HNGE Stock Forecast & Price Target

Hinge Health is positioned for strong fundamental compounding because management expects 2027 billings growth of 20%-25% even assuming flat yield and ASP, with revenue growth comfortably in the mid-to-high-20% range after 2026 billings rose more than 50%. Its outlook is reinforced by robust commercial momentum, including more than 5 million net new lives in verbal commitments, 3,270 contracted clients, 9 million migraine lives across 800 clients, and roughly 1 million SMB lives, alongside 88%-90% of addressable U.S. lives still lacking access to digital MSK care. The company also has meaningful operating leverage, with 2026 revenue guided to $879 million-$881 million, adjusted EBIT of $266 million-$268 million, and an expectation for at least 100 bps of operating-margin expansion in 2027 even as new products and care-team capacity build future growth.

Hinge Health is facing a negative setup because gross margin is expected to decline progressively as hiring continues, with management indicating it may stay around 86%-87% in 1Q27 before falling further. The bearish case also points to slower growth in FY27 if a weak spending environment emerges in 2H26, alongside risks from client losses, limited adoption of new offerings, weak operating leverage, and no improvement in adjusted EBITDA margin. Competitive pressure, regulatory shifts, and customer concentration are also material, as the top three partners—HCSC, Elevance Health, and Aetna—account for more than 40% of revenue year-to-date 2025.